US20100303895A1 - Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders - Google Patents

Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Download PDF

Info

Publication number
US20100303895A1
US20100303895A1 US12/526,930 US52693008A US2010303895A1 US 20100303895 A1 US20100303895 A1 US 20100303895A1 US 52693008 A US52693008 A US 52693008A US 2010303895 A1 US2010303895 A1 US 2010303895A1
Authority
US
United States
Prior art keywords
cytarabine
daunorubicin
dose
cpx
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/526,930
Other languages
English (en)
Inventor
Arthur Louie
Christine Swenson
Lawrence Mayer
Andrew Janoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celator Pharmaceuticals Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100303895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US12/526,930 priority Critical patent/US20100303895A1/en
Assigned to CELATOR PHARMACEUTICALS CORP. reassignment CELATOR PHARMACEUTICALS CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANOFF, ANDREW, MAYER, LAWRENCE, SWENSON, CHRISTINE, LOUIE, ARTHUR
Publication of US20100303895A1 publication Critical patent/US20100303895A1/en
Assigned to TMP NOMINEE II, LLC, WORKING OPPORTUNITY FUND (EVCC) LTD., VENTURES WEST 7 U.S. LIMITED PARTNERSHIP, THOMAS, MCNERNEY & PARTNERS II, L.P., GARDEN STATE LIFE SCIENCES VENTURE FUND, L.P., QUAKER BIOVENTURES, L.P., DOMAIN PARTNERS VI, L.P., BDC CAPITAL INC., VENTURES WEST 7 LIMITED PARTNERSHIP, TMP ASSOCIATES II, L.P. reassignment TMP NOMINEE II, LLC SECURITY AGREEMENT Assignors: CELATOR PHARMACEUTICALS, INC.
Assigned to CELATOR PHARMACEUTICALS, INC. reassignment CELATOR PHARMACEUTICALS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: BDC CAPITAL INC., DOMAIN PARTNERS VI, L.P., GARDEN STATE LIFE SCIENCES VENTURE FUND, L.P., QUAKER BIOVENTURES, L.P., THOMAS, MCNERNEY & PARTNERS II, L.P., TMP ASSOCIATES II, L.P., TMP NOMINEE II, LLC, VENTURES WEST 7 LIMITED PARTNERSHIP, VENTURES WEST 7 U.S. LIMITED PARTNERSHIP, WORKING OPPORTUNITY FUND (EVCC) LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
US12/526,930 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders Abandoned US20100303895A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/526,930 US20100303895A1 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
US12/526,930 US20100303895A1 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (1)

Publication Number Publication Date
US20100303895A1 true US20100303895A1 (en) 2010-12-02

Family

ID=39690832

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/032,583 Active 2029-04-01 US8092828B2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
US12/526,930 Abandoned US20100303895A1 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/032,583 Active 2029-04-01 US8092828B2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Country Status (20)

Country Link
US (2) US8092828B2 (el)
EP (3) EP4046640A1 (el)
JP (1) JP5314600B2 (el)
KR (2) KR20100014441A (el)
CN (1) CN105998046A (el)
AU (1) AU2008216083B2 (el)
CA (1) CA2678332C (el)
CY (1) CY1119631T1 (el)
DK (2) DK2120568T3 (el)
ES (2) ES2650167T3 (el)
FR (1) FR22C1034I2 (el)
HK (1) HK1253378A1 (el)
HR (1) HRP20220428T3 (el)
HU (2) HUE058334T2 (el)
NL (1) NL301185I2 (el)
NO (1) NO2120568T3 (el)
PL (2) PL2120568T3 (el)
PT (2) PT3300601T (el)
SI (1) SI3300601T1 (el)
WO (1) WO2008101214A2 (el)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CA3114002A1 (en) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20060057111A1 (en) * 2004-08-13 2006-03-16 Gunnar Hedlund Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
US20060165649A1 (en) * 2002-11-06 2006-07-27 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20060165771A1 (en) * 2001-10-03 2006-07-27 Paul Tardi Compositions for delivery of drug combinations
US20070286897A1 (en) * 2004-04-22 2007-12-13 Celator Pharmaceuticals, Inc. Liposomal Formulations of Anthracycline Agents and Cytidine Analogs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP2006508119A (ja) * 2002-11-06 2006-03-09 ワイス 急性白血病および骨髄異形成症候群の治療のための組み合わせ療法
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165771A1 (en) * 2001-10-03 2006-07-27 Paul Tardi Compositions for delivery of drug combinations
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20060165649A1 (en) * 2002-11-06 2006-07-27 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20070286897A1 (en) * 2004-04-22 2007-12-13 Celator Pharmaceuticals, Inc. Liposomal Formulations of Anthracycline Agents and Cytidine Analogs
US20060057111A1 (en) * 2004-08-13 2006-03-16 Gunnar Hedlund Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes

Also Published As

Publication number Publication date
DK2120568T3 (en) 2017-12-11
WO2008101214A3 (en) 2008-11-20
KR20150038752A (ko) 2015-04-08
HRP20220428T3 (hr) 2022-05-27
KR20100014441A (ko) 2010-02-10
EP2120568A2 (en) 2009-11-25
AU2008216083B2 (en) 2014-02-06
US8092828B2 (en) 2012-01-10
AU2008216083A2 (en) 2009-09-24
CA2678332C (en) 2015-06-02
CN105998046A (zh) 2016-10-12
JP2010519224A (ja) 2010-06-03
EP3300601A1 (en) 2018-04-04
FR22C1034I2 (fr) 2023-06-30
EP2120568B1 (en) 2017-11-15
EP4046640A1 (en) 2022-08-24
SI3300601T1 (sl) 2022-05-31
FR22C1034I1 (fr) 2022-09-09
PT2120568T (pt) 2017-12-04
CY1119631T1 (el) 2018-04-04
HUE058334T2 (hu) 2022-07-28
US20080199515A1 (en) 2008-08-21
EP2120568A4 (en) 2010-04-21
JP5314600B2 (ja) 2013-10-16
PT3300601T (pt) 2022-04-21
EP3300601B1 (en) 2022-01-12
HK1253378A1 (zh) 2019-06-14
WO2008101214A2 (en) 2008-08-21
ES2650167T3 (es) 2018-01-17
AU2008216083A1 (en) 2008-08-21
NL301185I2 (nl) 2022-07-21
DK3300601T3 (da) 2022-03-21
NO2120568T3 (el) 2018-04-14
PL3300601T3 (pl) 2022-05-02
PL2120568T3 (pl) 2018-03-30
HUS2200032I1 (hu) 2022-07-28
ES2909903T3 (es) 2022-05-10
CA2678332A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
US8092828B2 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
US8431806B2 (en) Liposomal formulations of anthracycline agents and cytidine analogs
AU2006306108B2 (en) Fixed ratio drug combination treatments for solid tumors
US20090074848A1 (en) Combination formulations of cytidine analogs and platinum agents
CN101657098A (zh) 用于治疗造血性癌症和增殖性病症的固定药物比例
Thomas et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia
US20200390702A1 (en) Liposomal taxanes for treatment of sclc
WO1997025044A1 (en) Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELATOR PHARMACEUTICALS CORP., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOUIE, ARTHUR;SWENSON, CHRISTINE;MAYER, LAWRENCE;AND OTHERS;SIGNING DATES FROM 20100125 TO 20100201;REEL/FRAME:024104/0710

AS Assignment

Owner name: QUAKER BIOVENTURES, L.P., PENNSYLVANIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: DOMAIN PARTNERS VI, L.P., NEW JERSEY

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: GARDEN STATE LIFE SCIENCES VENTURE FUND, L.P., PEN

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: WORKING OPPORTUNITY FUND (EVCC) LTD., CANADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: VENTURES WEST 7 LIMITED PARTNERSHIP, CANADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: VENTURES WEST 7 U.S. LIMITED PARTNERSHIP, CANADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: THOMAS, MCNERNEY & PARTNERS II, L.P., CONNECTICUT

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: TMP ASSOCIATES II, L.P., CONNECTICUT

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: TMP NOMINEE II, LLC, CONNECTICUT

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

Owner name: BDC CAPITAL INC., CANADA

Free format text: SECURITY AGREEMENT;ASSIGNOR:CELATOR PHARMACEUTICALS, INC.;REEL/FRAME:027423/0058

Effective date: 20111215

AS Assignment

Owner name: CELATOR PHARMACEUTICALS, INC., NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:THOMAS, MCNERNEY & PARTNERS II, L.P.;TMP NOMINEE II, LLC;TMP ASSOCIATES II, L.P.;AND OTHERS;REEL/FRAME:028385/0371

Effective date: 20120615

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION